Pegdinetanib (BMS-844203; CT-322) is a selective inhibitor targeting VEGFR-2 (VEGFR), exhibiting dissociation constants (Kd) of 11 nM and 250 nM and half-maximal inhibitory concentrations (IC50) of 16 nM and 240 nM for human and murine VEGFR-2, respectively. It demonstrates no affinity for VEGFR-1 or VEGFR-3. Its effectiveness extends to antitumor activity [1].